- Home
- GNTA vs VERU Comparison
GNTA vs VERU Comparison
Compare GNTA & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- VERU
- Stock Information
- Founded
- GNTA 2014
- VERU 1971
- Country
- GNTA Italy
- VERU United States
- Employees
- GNTA N/A
- VERU N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- VERU Health Care
- Exchange
- GNTA Nasdaq
- VERU Nasdaq
- Market Cap
- GNTA 81.2M
- VERU 94.5M
- IPO Year
- GNTA 2021
- VERU 1990
- Fundamental
- Price
- GNTA $3.06
- VERU $0.58
- Analyst Decision
- GNTA Strong Buy
- VERU Strong Buy
- Analyst Count
- GNTA 1
- VERU 2
- Target Price
- GNTA $25.00
- VERU $4.00
- AVG Volume (30 Days)
- GNTA 8.5K
- VERU 4.4M
- Earning Date
- GNTA 01-01-0001
- VERU 08-07-2025
- Dividend Yield
- GNTA N/A
- VERU N/A
- EPS Growth
- GNTA N/A
- VERU N/A
- EPS
- GNTA N/A
- VERU N/A
- Revenue
- GNTA N/A
- VERU $16,886,419.00
- Revenue This Year
- GNTA N/A
- VERU N/A
- Revenue Next Year
- GNTA N/A
- VERU N/A
- P/E Ratio
- GNTA N/A
- VERU N/A
- Revenue Growth
- GNTA N/A
- VERU 134.43
- 52 Week Low
- GNTA $2.79
- VERU $0.45
- 52 Week High
- GNTA $7.28
- VERU $1.42
- Technical
- Relative Strength Index (RSI)
- GNTA 22.52
- VERU 52.23
- Support Level
- GNTA $3.70
- VERU $0.56
- Resistance Level
- GNTA $6.12
- VERU $0.74
- Average True Range (ATR)
- GNTA 0.34
- VERU 0.05
- MACD
- GNTA -0.14
- VERU -0.00
- Stochastic Oscillator
- GNTA 0.33
- VERU 36.26
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.